Roche Holding AG (STU:RHOA) Cyclically Adjusted PB Ratio: (As of Aug. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:RHOA Roche Holding AG STU:RHOA
63 GF Score
Price €392.40
GF Value €289.45
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roche Holding AG Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Roche Holding AG  (STU:RHOA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Roche Holding AG Cyclically Adjusted PB Ratio Related Terms


Roche Holding AG Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Roche Holding AG's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roche Holding AG Cyclically Adjusted PB Ratio Chart

Roche Holding AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.90 9.09 7.24 7.19 8.83

Roche Holding AG Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 7.19 0.00 8.83 0.00

STU:RHOA vs LLY, JNJ, ABBV: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - General subindustry, Roche Holding AG's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Roche Holding AG Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Roche Holding AG's Cyclically Adjusted PB Ratio falls into.


STU:RHOA
63GF Score
Roche Holding AG STU:RHOA
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Roche Holding AG Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Roche Holding AG's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec25 is calculated as:

For example, Roche Holding AG's adjusted Book Value per Share data for the fiscal year that ended in Dec25 was:

Adj_Book=Book Value per Share/CPI of Dec25 (Change)*Current CPI (Dec25)
=45.529/107.2000*107.2000
=45.529

Current CPI (Dec25) = 107.2000.

Roche Holding AG Annual Data

Book Value per Share CPI Adj_Book
201612 26.101 99.380 28.155
201712 26.512 100.213 28.360
201812 28.668 100.906 30.456
201912 35.050 101.063 37.178
202012 39.414 100.241 42.150
202112 29.400 101.776 30.967
202212 35.492 104.666 36.351
202312 38.990 106.461 39.261
202412 42.778 107.128 42.807
202512 45.529 107.200 45.529

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Roche Holding AG (STU:RHOA) Overvalued in 2026?

Based on GuruFocus' analysis, Roche Holding AG stock appears to be overvalued. The current stock price of €392.40 is trading 35.6% above its estimated GF Value™ of €289.45. GuruFocus considers Roche Holding AG to be Significantly Overvalued.

Key valuation signals for STU:RHOA:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €289.45 vs. price of €392.40 (35.6% above fair value)
  • GF Score™: 63/100 with 7 warning signs

No single metric tells the full story. See the STU:RHOA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Roche Holding AG Business Description

Address Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
63GF Score

Get the complete analysis for STU:RHOA

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€392.40
Price
€289.45
GF Value